Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery

NCT00333255 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

267

Enrollment

INDUSTRY

Sponsor class

Conditions

Cataract

Interventions

DRUG: Nepafenac Ophthalmic Suspension, 0.1%

Sponsor

Alcon Research